Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 17, 2014

View Archived Issues

U.S. and U.K. affiliation to support early-stage drug discovery and development

New Oncology to collaborate with National Cancer Centre Singapore on NEO platform

Asuragen launches Quantidex DNA Assay

NIAID contract supports Integral Molecular's work on Ebola and HCV antibody response

Affiris plans pilot studies of vaccines for Parkinson's disease and multiple system atrophy

Fundacion MEDINA discloses new antifungal compounds

First patient dosed in phase II trial of aramchol for the treatment of cholesterol gallstones

Roche patents novel CB2 receptor agonists

New DLK inhibitors designed at Roche and Genentech

Sunshine Lake Pharma patents novel aminoquinazoline derivatives

Nerviano Medical Sciences discloses novel antitumor anthracyclines

INV-17 demonstrates safety and therapeutic activity in a model of rheumatoid arthritis

Non-propagating dengue vaccine induces neonatal immunity in mice

Phase II results for the HBV and HDV entry inhibitor Myrcludex B

Insulin sparing activity of adenoviral protein E4orf1 may be beneficial for insulin resistance

Cytomedix changes name to Nuo Therapeutics

RGFP-966, an epigenetic HDAC3 inhibitor, tested in a rat cocaine-abuse model

Alnylam reports phase II results for transthyretin-targeting RNAi in cardiac amyloidosis

Merck KGaA and Pfizer establish global strategic alliance in immuno-oncology

Genticel completes enrollment in phase II HPV trial of ProCervix

Roche returns rights for INO-5150 to Inovio, maintains INO-1800 collaboration

Puma Biotechnology discloses results from phase II study comparing neratinib and trastuzumab

FDA approves Genzyme's Lemtrada for relapsing MS

FDA approves Avastin for platinum-resistant recurrent ovarian cancer

Temozolomide-perillyl alcohol conjugate granted FDA orphan status for glioma

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...